<DOC>
	<DOCNO>NCT02772640</DOCNO>
	<brief_summary>The aim study demonstrate , whether time day administration study drug ( contain rosuvastatin ezetimibe ) impact effectiveness lipid-lowering therapy .</brief_summary>
	<brief_title>Effectiveness Treatment Hypercholesterolemia With Rosuvastatin Ezetimibe</brief_title>
	<detailed_description>The current guideline recommend statin drug first choice treatment hypercholesterolemia . If target LDL cholesterol achieve , combination statin cholesterol absorption inhibitor -ezetimibe may consider . According meta-analyzes study assess statin , 1.0 mmol / L ( ~ 40 mg / dL ) reduction LDL-C correspond 10 % reduction all-cause mortality 20 % reduction number death coronary artery disease . Each 1 mmol / L ( 40 mg / dL ) reduction LDL-C also translate 23 % 17 % reduction risk major coronary event stroke , respectively . Similar result concern efficacy safety lipid-lowering therapy use statin obtain meta-analyzes study primary prevention . Statins heterogenous group drug respect LDL-C reduction power . So far , potent statin rosuvastatin . Despite intensive statin therapy provide , large group patient still reach therapeutic goal . Statin dose titration seem less effective compare combined therapy statin ezetimibe . The combination statin ezetimibe reduce LDL-C additional 15-20 % . Tablets comprise drug ( statin ezetimibe ) simplify drug administration increase probability drug compliance . This may increase probability achieve therapeutic goal hypercholesterolemia treatment . Taking account metabolism cholesterol possible drug-drug interaction recommend administer simvastatin evening . Rosuvastatin may administer time day . The study design open-label , single-center , cross-over study evaluate effectiveness combine therapy rosuvastatin ezetimibe hypercholesterolemia depend time day administration study treatment . After enrollment participant allocate two arm , receive rosuvastatin ezetimibe . The study drug ( rosuvastatin ezetimibe ) give : 1 ) morning ( 8:00 ) 6 week even next 6 week ; 2 ) evening ( 20:00 ) first 6 week morning follow 6 week . The change total cholesterol LDL-cholesterol 6 12 week test therapy measure primary outcome study . Moreover , parameter include : HDL-cholesterol , triglyceride , apolipoprotein B ( ApoB ) , ApoAI , nonHDL-cholesterol , sd-LDL-cholesterol , lipoprotein ( ) , glucose , HBA1c , high sensitivity C reactive protein ( hsCRP ) , ALT , aspartate aminotransferase ( AST ) , creatine kinase ( CK ) assess secondary outcome .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Hypercholesterolemia 2 . Ineffectiveness statin monotherapy treatment hypercholesterolemia least 6 week 1 . Active liver disease 2 . Unexplained persistent increase serum transaminase level , include 3 time upper limit normal activity one 3 . Severe renal impairment ( creatinine clearance &lt; 30 ml / min ) 4 . Myopathy 5 . Concomitant treatment cyclosporine , gemfibrozil 6 . Pregnancy 7 . Lactation 8 . Women childbearing age use effective method contraception 9 . Symptoms muscle damage use statin fibrates past . 10 . The activity creatine kinase &gt; 5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Rosuvastatin</keyword>
	<keyword>Statin</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Compliance</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>Secondary prevention</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Cholesterol absorption inhibitor</keyword>
</DOC>